Zhi Dai

8.4k total citations · 3 hit papers
97 papers, 5.4k citations indexed

About

Zhi Dai is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Zhi Dai has authored 97 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Molecular Biology, 27 papers in Cancer Research and 25 papers in Oncology. Recurrent topics in Zhi Dai's work include RNA modifications and cancer (13 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Zhi Dai is often cited by papers focused on RNA modifications and cancer (13 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Zhi Dai collaborates with scholars based in China, Ethiopia and United States. Zhi Dai's co-authors include Jia Fan, Jian Zhou, Zheng‐Jun Zhou, Shao‐Lai Zhou, Xiaowu Huang, Ying‐Hong Shi, Zhiqiang Hu, Zhen‐Bin Ding, Zheng Wang and Guo‐Huan Yang and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Zhi Dai

96 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib

2016 662 citations Shao‐Lai Zhou, Zheng‐Jun Zhou et al. profile →
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma

2011 521 citations Jian Zhou, Jie Hu et al. profile →
Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma

2024 71 citations Feng Zhang, Suiyi Wu et al. Cancer Communications profile →

Peers

Countries citing papers authored by Zhi Dai

Since Specialization

Citations

This map shows the geographic impact of Zhi Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhi Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhi Dai more than expected).

Fields of papers citing papers by Zhi Dai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhi Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhi Dai. The network helps show where Zhi Dai may publish in the future.

Co-authorship network of co-authors of Zhi Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Zhi Dai. A scholar is included among the top collaborators of Zhi Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhi Dai. Zhi Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hypoxia-related CircARSB Modulates lipid metabolism and innate immune crosstalk to influence immune checkpoint inhibitor response in hepatocellular carcinoma 2025 ·Cancer Letters ·(unknown), (unknown), Gui‐Qi Zhu, Peiling Zhang, Shiping Chen, Bing Quan, Jun-Xian Du, (unknown), (unknown), Jian Zhou, (unknown), (unknown), Yulong Lei, Zhi Dai	0
2	Targeting GSDME-mediated macrophage polarization for enhanced antitumor immunity in hepatocellular carcinoma 2024 ·Cellular and Molecular Immunology ·Shiping Chen, Peiling Zhang, Gui‐Qi Zhu, Biao Wang, (unknown), (unknown), (unknown), Yi Yang, Jun-Xian Du, (unknown), Jian Zhou, Jia Fan, Zhi Dai	14
3	Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma breakdown → 2024 ·Cancer Communications ·(unknown), (unknown), Feng Zhang, Suiyi Wu, Gui‐Qi Zhu, Peiling Zhang, Shiping Chen, Jun-Xian Du, (unknown), (unknown), Yi Yang, (unknown), Jian Zhou, (unknown), Zhi Dai	71
4	Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence 2022 ·Signal Transduction and Targeted Therapy ·Shao‐Lai Zhou, Zheng‐Jun Zhou, Chengli Song, Haoyang Xin, Zhiqiang Hu, Chu‐Bin Luo, (unknown), Jia Li, Zhi Dai, Xin‐Rong Yang, Ying‐Hong Shi, Zheng Wang, Xiaowu Huang, Jia Fan, Jian Zhou	22
5	Targeting HNRNPM Inhibits Cancer Stemness and Enhances Antitumor Immunity in Wnt-activated Hepatocellular Carcinoma 2022 ·Cellular and Molecular Gastroenterology and Hepatology ·Guiqi Zhu, Yi Wang, (unknown), Wei‐Ren Liu, Shuangshuang Dong, Erbao Chen, Jialiang Cai, (unknown), Jun-Xian Du, Lina Song, Shiping Chen, Lei Yu, Zheng‐Jun Zhou, Zheng Wang, Jian Zhou, Ying‐Hong Shi, Jia Fan, Zhi Dai	29
6	Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma 2022 ·Frontiers in Immunology ·Jialiang Cai, Suiyi Wu, Feng Zhang, Zhi Dai	4
7	The expression profiles and prognostic values of HSP70s in hepatocellular carcinoma 2021 ·Cancer Cell International ·Ben Wang, Tian Lan, Han Xiao, (unknown), Chao Wei, (unknown), (unknown), Rongfa Yuan, Xin Yu, Zhigang Hu, Hua‐Jun Wu, Zhi Dai, (unknown)	38
8	Yinzhihuang Oral Liquid Ameliorates Hyperbilirubinemia Induced by δ‐Aminolevulinic Acid and Novobiocin in Neonatal Rats 2021 ·Chemistry & Biodiversity ·Jing Han, Caiyu Li, Zhi Dai, (unknown), (unknown), Yong Wang, Youcai Zhang	4
9	Metabolomics reveal dynamic changes in eicosanoid profile in patients with ST‐elevation myocardial infarction after percutaneous coronary intervention 2020 ·Clinical and Experimental Pharmacology and Physiology ·(unknown), Zhi Dai, (unknown), Xiao Wang, Wei Gong, (unknown), Zhiqing He, Ru Ding, Xu Zhang, Shaoping Nie, Chun Liang	8
10	The Antioxidative Action of ZTP by Increasing Nrf2/ARE Signal Pathway 2019 ·Evidence-based Complementary and Alternative Medicine ·Liang Yang, Bing Xu, (unknown), Zhi Dai, Yong Wang, Qiongya Li, (unknown), Nuomin Li, Hong Qing	5
11	Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization 2018 ·Cancer Management and Research ·Guiqi Zhu, Kang Wang, (unknown), Yujie Zhou, Yi Yang, Erbao Chen, Zheng‐Jun Zhou, Shao‐Lai Zhou, Ying‐Hong Shi, Jian Zhou, Zhi Dai	12
12	Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis 2018 ·Journal of Cancer ·Chenyang Tao, Wei‐Ren Liu, Lei Jin, Zheng Tang, Meng‐Xin Tian, Xi‐Fei Jiang, Han Wang, Pei‐Yun Zhou, Yuan Fang, Zhen‐Bin Ding, Yuan‐Fei Peng, Zhi Dai, Shuang–Jian Qiu, Jian Zhou, Jia Fan, Ying‐Hong Shi	17
13	HNRNPAB Induces Epithelial–Mesenchymal Transition and Promotes Metastasis of Hepatocellular Carcinoma by Transcriptionally Activating SNAIL 2014 ·Cancer Research ·Zheng‐Jun Zhou, Zhi Dai, Shao‐Lai Zhou, Zhiqiang Hu, Qing Chen, Yiming Zhao, Ying‐Hong Shi, Qiang Gao, Wei‐Zhong Wu, Shuang–Jian Qiu, Jian Zhou, Jia Fan	88
14	Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma 2013 ·Clinical Cancer Research ·Jie-Yi Shi, Qiang Gao, Zhichao Wang, Jian Zhou, Xiaoying Wang, Zhihui Min, Ying‐Hong Shi, Guo‐Ming Shi, Zhen‐Bin Ding, Ai‐Wu Ke, Zhi Dai, Shuang‐Jian Qiu, Kang Song, Jia Fan	182
15	MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression 2013 ·Carcinogenesis ·Kai Zhu, Qi Pan, Xin Zhang, Ling–Qun Kong, Jia Fan, Zhi Dai, Lu Wang, Xin‐Rong Yang, Jie Hu, Jin-Liang Wan, Yiming Zhao, Zhonghua Tao, Zong‐Tao Chai, Haiying Zeng, Zhao–You Tang, Hui‐Chuan Sun, Jian Zhou	100
16	Low Level of Low-Density Lipoprotein Receptor-Related Protein 1 Predicts an Unfavorable Prognosis of Hepatocellular Carcinoma after Curative Resection 2012 ·PLoS ONE ·Xiaoyong Huang, Guo‐Ming Shi, Ranjan Prasad Devbhandari, Ai‐Wu Ke, Yuwei Wang, Xiaoying Wang, Zheng Wang, Ying‐Hong Shi, Yong‐Sheng Xiao, Zhen‐Bin Ding, Zhi Dai, Yang Xu, Weiping Jia, Zhao–You Tang, Jia Fan, Jian Zhou	35
17	The Application of Experimental Design and Optimization Techniques in Optimization of Microbial Medium 2010 ·Microbiology, China ·Zhi Dai	1
18	CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery 2009 ·Clinical Cancer Research ·Xin‐Rong Yang, Yang Xu, Bin Yu, Jian Zhou, (unknown), Shuang–Jian Qiu, Ying‐Hong Shi, Xiaoying Wang, Zhi Dai, Guo‐Ming Shi, Bin Wu, Liming Wu, Guo‐Huan Yang, Boheng Zhang, Wenxin Qin, Jia Fan	129
19	Heat‐shock protein 27: A potential biomarker for hepatocellular carcinoma identified by serum proteome analysis 2005 ·PROTEOMICS ·Ju-Tao Feng, Yinkun Liu, Haiyan Song, Zhi Dai, Lun–Xiu Qin, Mohamad Radwan Almofti, Caiyun Fang, Haojie Lu, Pengyuan Yang, Zhao–You Tang	162
20	APPLICATION OF THE PRINCIPAL COMPONENT ANALYSIS TO THE STUDY OF SUSTAINABLE DEVELOPMENT OF THE CITY PRED SYSTEM--A Case Study of the 21 Cities in Guangdong Province 2002 ·Tropical Geography ·Zhi Dai	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact